A reader submitted the following question to [email protected], the Motley Fool's health care email address for reader questions and comments:
The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your biotech, what would be your #1 pick?
Health care analysts Michael Douglass and David Williamson both answered. Michael's pick was Merck's (MRK 0.92%) PD-1 inhibitor, immuno-oncology drug MK-3475. MK-3475 is set to go before the FDA, with its PDUFA date on October 28th for patients with unresectable or metastatic melanoma who have previously been treated with Yervoy. The drug is being tested in combination with therapies from Amgen and Incyte, and Merck is working quickly to get the drug approved for a number of indications.
Watch the video below for more details on why Michael picked MK-3475.
